GSK领导的癌症药物试验因未能对316名头部和颈部癌症病人进行治疗而停止,这与科学家Mark Smyth的有争议的研究有关。 A cancer drug trial led by GSK was stopped after failing to work in 316 head and neck cancer patients, tied to disputed research by scientist Mark Smyth.

以臭名昭著的澳大利亚科学家Mark Smyth的研究为基础的GSK癌症药物Nelistotug的第二阶段临床试验因316名头部和颈部癌症患者缺乏成效而停止。 A phase II clinical trial for GSK’s cancer drug nelistotug, based on research by disgraced Australian scientist Mark Smyth, has been halted due to lack of efficacy in 316 patients with head and neck cancer. Smyth的2014年基础研究将CD96与免疫抑制联系起来,此后在不当行为指控中一直受到质疑。 审判失败的原因是担心Smyth的2014年基础研究的可复制性。 The trial’s failure follows concerns over the reproducibility of Smyth’s foundational 2014 study linking CD96 to immune suppression, which has since been questioned amid misconduct allegations. 自那时起,GSK和Bristol Myers Squibb已经放弃了相关的药物方案,造成了巨大的财政损失,并使人们对依赖未经核实的药物开发研究感到关切。 GSK and Bristol Myers Squibb have since abandoned related drug programs, resulting in significant financial losses and raising concerns about reliance on unverified research in drug development.